Indigestion

Functional Dyspepsia (Non-Ulcer Dyspepsia) Pipeline Monitor, 2020 - ResearchAndMarkets.com

Retrieved on: 
Friday, July 24, 2020
Health, Pharmaceutical, Indigestion, Pyridines, Clinical medicine, Niacin, Organ systems, Branches of biology

The "Functional Dyspepsia (Non Ulcer Dyspepsia) Pipeline Research Monitor, 2020 - Drugs, Companies, Clinical Trials, R&D Pipeline Updates, Status and Outlook" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Functional Dyspepsia (Non Ulcer Dyspepsia) Pipeline Research Monitor, 2020 - Drugs, Companies, Clinical Trials, R&D Pipeline Updates, Status and Outlook" report has been added to ResearchAndMarkets.com's offering.
  • Good progress is anticipated during 2020 and 2021 with Functional Dyspepsia (Non Ulcer Dyspepsia) pipeline molecules advancing from pre-clinical investigation to completion of advanced Phase clinical trials.
  • This Functional Dyspepsia (Non Ulcer Dyspepsia) pipeline review explores high-potential early to late-stage pipeline projects with a continued focus on new insights, accelerated processes, and pipeline progression.
  • The competitive intelligence report on Functional Dyspepsia (Non Ulcer Dyspepsia) presents detailed insights into therapeutic drug pipeline development, industry news, deals, and analysis across the length and breadth of the Functional Dyspepsia (Non Ulcer Dyspepsia) pipeline.

Allakos Announces Positive Phase 1 Results with Antolimab (AK002) in Mast Cell Gastrointestinal Disease

Retrieved on: 
Tuesday, March 24, 2020
Medical specialties, Medicine, Digestive diseases, Immune system disorders, RTT, Eosinophilic esophagitis, Mastocytosis, Indigestion, Gastritis, Esophagitis, Eosinophil, Gastrointestinal disease

Allakos is conducting additional clinical studies to better characterize MGID and assess the disease prevalence in patients with chronic functional gastrointestinal symptoms including those with irritable bowel syndrome, functional dyspepsia, and chronic gastritis.

Key Points: 
  • Allakos is conducting additional clinical studies to better characterize MGID and assess the disease prevalence in patients with chronic functional gastrointestinal symptoms including those with irritable bowel syndrome, functional dyspepsia, and chronic gastritis.
  • The Companys lead antibody, antolimab (AK002), targets Siglec-8, an inhibitory receptor selectively expressed on human mast cells and eosinophils.
  • In these studies, antolimab eliminated blood and tissue eosinophils, inhibited mast cells and improved disease symptoms in patients with eosinophilic gastritis and/or eosinophilic duodenitis, eosinophilic esophagitis, mast cell gastrointestinal disease, severe allergic conjunctivitis, chronic urticaria, and indolent systemic mastocytosis.
  • These documents contain and identify important factors that could cause the actual results for Allakos to differ materially from those contained in Allakos forward-looking statements.

Global Antacids Market Report (2020 to 2022) - Identify Growth Segments for Investment - ResearchAndMarkets.com

Retrieved on: 
Monday, March 23, 2020
Health, Pharmaceutical, Digestive diseases, Medical specialties, Gastroenterology, RTT, Gastroesophageal reflux disease, Heartburn, Indigestion, Gastric acid, Antacids

Antacids Market Global Report 2020 from the author provides strategists, marketers and senior management with the critical information they need to assess the global antacids market.

Key Points: 
  • Antacids Market Global Report 2020 from the author provides strategists, marketers and senior management with the critical information they need to assess the global antacids market.
  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • The antacids market consists of sales of antacids which are used to neutralize stomach acid, and treat acid reflux, heartburn and indigestion.
  • Poor lifestyle choices resulting in higher prevalence of acidity is an important driver for the growth of the antacids market.

Global Pipeline Review for Functional (Non Ulcer) Dyspepsia - H1 2020 - ResearchAndMarkets.com

Retrieved on: 
Monday, February 3, 2020
Health, General Health, Indigestion

The "Functional (Non Ulcer) Dyspepsia - Pipeline Review, H1 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Functional (Non Ulcer) Dyspepsia - Pipeline Review, H1 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • The Functional (Non Ulcer) Dyspepsia (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Functional (Non Ulcer) Dyspepsia and features dormant and discontinued projects.
  • Formulate corrective measures for pipeline projects by understanding Functional (Non Ulcer) Dyspepsia (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

In The Longest-Running Post-Marketing Surveillance Study Of Its Type, Data At 24 Months On FDgard®, Presented At The American College Of Gastroenterology (ACG) Annual Meeting, Confirms Excellent Safety And Tolerability Profile Of This Nonprescription Pro

Retrieved on: 
Tuesday, October 29, 2019
Medical specialties, Academic journals, Medicine, Open access journals, Indigestion, Clinical and Translational Gastroenterology, Tolerability

This study, called Functional Dyspepsia Safety Update at 24 months (FDSU24), is a real-world surveillance study reporting on the safety and tolerability profile of FDgard(COLM-SST).

Key Points: 
  • This study, called Functional Dyspepsia Safety Update at 24 months (FDSU24), is a real-world surveillance study reporting on the safety and tolerability profile of FDgard(COLM-SST).
  • First, concomitant medications for FD symptoms were allowed in order to assess FDgard in a real-world setting.
  • Underscoring the importance of FDgard as a medical advance, Clinical and Translational Gastroenterology (CTG),a peer-reviewed journal, has published the results of FDREST.
  • The data showed a consistently high level of patient satisfaction and rapid improvement of FD symptoms with the product.

For The Third Year In A Row, Gastroenterologists Nationwide Endorse Nonprescription FDgard® For Functional Dyspepsia (Meal-Triggered Indigestion(i)) (ii)

Retrieved on: 
Friday, August 23, 2019
Woonsocket, Rhode Island, Indigestion, CVS Pharmacy, Pharmacy, Walgreens, Rite Aid, Medical specialties, Retailers, Companies

First, concomitant medications for FD symptoms were allowed in order to assess FDgard in a real-world setting.

Key Points: 
  • First, concomitant medications for FD symptoms were allowed in order to assess FDgard in a real-world setting.
  • FDREST provides further validation of FDgard as a PreMeal Companionfor the daily and proactive management of FD.
  • Nonprescription FDgard is available to patients in the digestive aisle in major retailers nationwide, including CVS/pharmacy, Rite Aid, Walgreens, select Walmart locations, and many grocery stores.
  • The ProVoice survey methodology validated the claim, at a 99 percent confidence level, that for the third year, "FDgard is the #1 gastroenterologist-recommended herbal product for patients with Functional Dyspepsia."

Rheumatoid Arthritis - Can its Onset be Delayed or Prevented

Retrieved on: 
Monday, June 10, 2019
Medicine, RTT, Health, Medical terminology, Articles, Disease, Preventive healthcare, Cure, Diabetes, Cardiovascular disease, Cancer, Indigestion

Identifying people before they develop the disorder could significantly alter the course of disease and spare people its damaging effects.

Key Points: 
  • Identifying people before they develop the disorder could significantly alter the course of disease and spare people its damaging effects.
  • While medications can control RA for many patients, very few experience a complete cure and are able to discontinue treatment.
  • "Most people are familiar with prevention for diseases such as diabetes, heart disease, or cancer," notes Dr. Deane.
  • That finding suggests that if individuals can be identified at the right time, future RA can be delayed or completely prevented.

Rheumatoid Arthritis - Can its Onset be Delayed or Prevented

Retrieved on: 
Monday, June 10, 2019
Medicine, RTT, Health, Medical terminology, Articles, Disease, Preventive healthcare, Cure, Diabetes, Cardiovascular disease, Cancer, Indigestion

Identifying people before they develop the disorder could significantly alter the course of disease and spare people its damaging effects.

Key Points: 
  • Identifying people before they develop the disorder could significantly alter the course of disease and spare people its damaging effects.
  • While medications can control RA for many patients, very few experience a complete cure and are able to discontinue treatment.
  • "Most people are familiar with prevention for diseases such as diabetes, heart disease, or cancer," notes Dr. Deane.
  • That finding suggests that if individuals can be identified at the right time, future RA can be delayed or completely prevented.

Functional (Non Ulcer) Dyspepsia Pipeline Review, H1 2019 Report Featuring Daewoong Pharmaceutical, RaQualia Pharma, & Zeria Pharmaceutical - ResearchAndMarkets.com

Retrieved on: 
Thursday, May 23, 2019
Health, Pharmaceutical, Indigestion

The "Functional (Non Ulcer) Dyspepsia - Pipeline Review, H1 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Functional (Non Ulcer) Dyspepsia - Pipeline Review, H1 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • Functional (Non Ulcer) Dyspepsia - Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development for Functional (Non Ulcer) Dyspepsia (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.
  • The Functional (Non Ulcer) Dyspepsia (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Functional (Non Ulcer) Dyspepsia and features dormant and discontinued projects.
  • The pipeline guide reviews pipeline therapeutics for Functional (Non Ulcer) Dyspepsia (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.

Lolleez® Parent Company Expands Family with Sibling Brand Tumeez™

Retrieved on: 
Wednesday, October 24, 2018
Lollipops, Candy, Indigestion, Heartburn

WASHINGTON, Conn., Oct. 24, 2018 /PRNewswire/ -- Momeez Choice, the parent company of Lolleez Organic Throat Soothing Lollipops for Kids, is pleased to announce the birth of sibling brand, Tumeez Organic Tummy Soothing Lollipops for Kids.

Key Points: 
  • WASHINGTON, Conn., Oct. 24, 2018 /PRNewswire/ -- Momeez Choice, the parent company of Lolleez Organic Throat Soothing Lollipops for Kids, is pleased to announce the birth of sibling brand, Tumeez Organic Tummy Soothing Lollipops for Kids.
  • Tumeez was created by a mom, for kids, to help ease and relieve heartburn, acid indigestion and an upset tummy.
  • Abdominal ailments are common in kids, especially school age, with the main culprits being diet, stress, and growing pains.
  • Tumeez come in a variety pack of 10 pops in Grape and Apple flavors for a suggested retail price of $5.99.